|
Gene: SNX22 |
Gene summary for SNX22 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SNX22 | Gene ID | 79856 |
Gene name | sorting nexin 22 | |
Gene Alias | SNX22 | |
Cytomap | 15q22.31 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024R5Y5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79856 | SNX22 | HCC1 | Human | Liver | HCC | 6.25e-12 | 1.05e+00 | 0.5336 |
79856 | SNX22 | HCC2 | Human | Liver | HCC | 7.60e-21 | 2.56e+00 | 0.5341 |
79856 | SNX22 | HCC5 | Human | Liver | HCC | 2.01e-15 | 1.57e+00 | 0.4932 |
79856 | SNX22 | S028 | Human | Liver | HCC | 3.23e-06 | 4.16e-01 | 0.2503 |
79856 | SNX22 | S029 | Human | Liver | HCC | 1.10e-05 | 3.27e-01 | 0.2581 |
79856 | SNX22 | male-WTA | Human | Thyroid | PTC | 1.24e-61 | 8.10e-01 | 0.1037 |
79856 | SNX22 | female-WTA | Human | Thyroid | PTC | 9.06e-06 | 5.82e-01 | 0.0726 |
79856 | SNX22 | PTC01 | Human | Thyroid | PTC | 3.51e-49 | 1.16e+00 | 0.1899 |
79856 | SNX22 | PTC03 | Human | Thyroid | PTC | 6.41e-18 | 1.09e+00 | 0.1784 |
79856 | SNX22 | PTC04 | Human | Thyroid | PTC | 1.84e-56 | 1.20e+00 | 0.1927 |
79856 | SNX22 | PTC05 | Human | Thyroid | PTC | 5.63e-43 | 2.21e+00 | 0.2065 |
79856 | SNX22 | PTC06 | Human | Thyroid | PTC | 1.03e-76 | 2.25e+00 | 0.2057 |
79856 | SNX22 | PTC07 | Human | Thyroid | PTC | 8.46e-65 | 1.39e+00 | 0.2044 |
79856 | SNX22 | ATC4 | Human | Thyroid | ATC | 7.17e-04 | 4.07e-02 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SNX22 | SNV | Missense_Mutation | rs768182173 | c.271C>A | p.Leu91Met | p.L91M | Q96L94 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SNX22 | SNV | Missense_Mutation | novel | c.451N>T | p.Pro151Ser | p.P151S | Q96L94 | protein_coding | tolerated(0.29) | benign(0.048) | TCGA-AA-3980-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SNX22 | SNV | Missense_Mutation | c.337G>T | p.Asp113Tyr | p.D113Y | Q96L94 | protein_coding | tolerated(0.06) | probably_damaging(0.998) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
SNX22 | SNV | Missense_Mutation | rs111942276 | c.464C>T | p.Ser155Leu | p.S155L | Q96L94 | protein_coding | tolerated(0.86) | benign(0) | TCGA-AG-4007-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
SNX22 | SNV | Missense_Mutation | rs771187244 | c.434N>G | p.Asp145Gly | p.D145G | Q96L94 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SNX22 | SNV | Missense_Mutation | novel | c.408N>T | p.Gln136His | p.Q136H | Q96L94 | protein_coding | tolerated(1) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SNX22 | SNV | Missense_Mutation | novel | c.505T>A | p.Tyr169Asn | p.Y169N | Q96L94 | protein_coding | deleterious(0) | benign(0.11) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
SNX22 | SNV | Missense_Mutation | novel | c.245N>A | p.Gly82Asp | p.G82D | Q96L94 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SNX22 | SNV | Missense_Mutation | c.476T>C | p.Val159Ala | p.V159A | Q96L94 | protein_coding | tolerated(0.07) | benign(0.084) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SNX22 | insertion | Frame_Shift_Ins | novel | c.188_189insC | p.Ser65LeufsTer53 | p.S65Lfs*53 | Q96L94 | protein_coding | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |